Drug Profile
Anamorelin - Helsinn Therapeutics/Ono Pharmaceutical
Alternative Names: Adlumiz; ANAM; Anamorelin HCl; Anamorelin hydrochloride; ONO-7643; RC-1291; RC-1291 HCl; ST-1291Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Developer Helsinn Therapeutics; Ono Pharmaceutical
- Class Appetite stimulants; Piperidines; Small molecules
- Mechanism of Action Ghrelin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cachexia
- Registered Anorexia
- Phase II Fatigue
Most Recent Events
- 13 Feb 2023 Helsinn Therapeutics completes a phase III trial in Cachexia and Anorexia in USA, Bulgaria, Hungary, Italy, Romania, Russia, Serbia (PO) (NCT03743051)
- 16 Feb 2022 Phase-II clinical trials in Anorexia (Prevention) in USA (PO) (NCT04844970)
- 16 Feb 2022 Phase-II clinical trials in Cachexia (Prevention) in USA (PO) (NCT04844970)